Nanosphere Submits Cardiac Test to FDA | GenomeWeb

NEW YORK (GenomeWeb News) – Nanosphere today said that it has submitted a 510(k) application with the US Food and Drug Administration for its cardiac troponin I test.

The firm said that the test is used to provide early diagnosis of myocardial infarction and risk stratification for acute coronary syndromes. The test runs on the firm's Verigene molecular diagnostics platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.